2020 Safety Therapy 
Aesthetics Advisor
AUGUST 18, 2023
Key Points: A few studies show that NAD+ IV therapy can alleviate alcohol and drug addiction, as well as Parkinson’s disease, but no studies have examined its effects on aging. Oral administration of NAD+ boosting therapy is safer, more cost effective, and more consistently dosed than intravenous administartion.
Lipgloss and Aftershave
NOVEMBER 1, 2024
Research shows that combining treatments improves efficacy, reduces recurrence rates, and minimizes side effects, particularly in addressing conditions like melasma, sunspots, and post-inflammatory hyperpigmentation (Anderson & Anderson, 2020). Dermatologic Therapy. Goldberg, D. Aesthetic Surgery Journal. Dermatology Research.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Aesthetic Advancements Institute (AAI)
OCTOBER 18, 2023
microneedling market has seen a consistent upward trajectory since 2020, translating to more informed and effective treatments by practitioners. With the influx of devices in the market, using only FDA-approved microneedling devices becomes paramount to ensure safety and credibility. With Acne being a prime concern, the U.S.
Aesthetics Advisor
AUGUST 15, 2023
Curcumin may help increase healthy p53 levels, and it has been shown to be a potentially effective cancer therapy supplement. Since fenbendazole is a veterinary medicine, and is not licensed for human use and there is no specific human safety data available. Click here to buy Theracurmin HP by Integrative Therapeutics (Amazon) 3.
Aesthetics Advisor
JANUARY 6, 2024
In 2020 alone, there were approximately 19.3 The conclusion drawn by researchers is that considering the relative safety of aspirin, it should be considered as a preventative measure for cancer. Furthermore, there is evidence of aspirin’s role in preventing cancer metastasis. Cancer is one of the leading causes of global mortality.
The Dermatology Digest
MAY 23, 2021
So we’re looking for a way to sensitize or in some cases re-sensitize this disease to immune checkpoint inhibitor therapy.” As of November 2020, interim results of the phase 1b stage demonstrated a confirmed overall response rate (ORR) of 21%. 3 The first patient in the MCC cohort was dosed in June 2020. November 9-14, 2020.
The Dermatology Digest
MAY 15, 2021
So we’re looking for a way to sensitize or in some cases re-sensitize this disease to immune checkpoint inhibitor therapy.” As of November 2020, interim results of the phase 1b stage demonstrated a confirmed overall response rate (ORR) of 21%. 3 The first patient in the MCC cohort was dosed in June 2020. November 9-14, 2020.
Expert insights. Personalized for you.
36 
Let's personalize your content